千红制药(002550) - 2024 Q3 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders for the first three quarters of 2024 is expected to be 309.58 million yuan, representing a year-on-year increase of 56.47% compared to 197.86 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is expected to be 215.10 million yuan, an increase of 29.74% from 165.79 million yuan in the previous year [2]. - The basic earnings per share for the first three quarters is expected to be 0.25 yuan, up from 0.15 yuan in the same period last year [2]. - For the third quarter of 2024, the net profit attributable to shareholders is expected to be 126.79 million yuan, a year-on-year increase of 60.84% compared to 78.83 million yuan [3]. - The net profit after deducting non-recurring gains and losses for the third quarter is expected to be 35.64 million yuan, a decrease of 34.09% from 54.08 million yuan in the previous year [3]. - The basic earnings per share for the third quarter is expected to be 0.10 yuan, compared to 0.06 yuan in the same period last year [3]. Non-Recurring Gains and Losses - The company received a settlement payment of 85 million yuan related to a dispute with Jianyuan Trust, contributing to the non-recurring gains and losses of 94.48 million yuan during the reporting period [5]. Profitability and Expenses - The gross profit margin has continued to improve compared to the same period last year, while the sales expense ratio has gradually decreased, leading to sustained growth in net profit [5]. Caution and Auditing - The performance forecast has not been audited by the accounting firm, and specific financial data will be confirmed in the third-quarter report [4]. - Investors are advised to exercise caution as the performance forecast is based on preliminary estimates by the company's finance department [5].